Bone marrow aspirate concentrate is an autologous preparation — marrow drawn from your own body, concentrated, and injected at a target. What it is not is a settled treatment with established long-term superiority, and it does not regrow or regenerate cartilage. A 2025 narrative review in Medicina (Kaunas) on BMAC for knee osteoarthritis reports short- to mid-term symptomatic relief and functional improvement, alongside inconsistent findings and long-term efficacy that has yet to be firmly established against comparators.
What BMAC is
An autologous concentrate, prepared from your own marrow
BMAC begins with a marrow aspirate, which is then concentrated before delivery. Because the starting material comes from the patient, it sits in a different category from anything manufactured from donor tissue.
The 2025 narrative review describes BMAC as enriched with mesenchymal stem cells and bioactive growth factors, and discusses proposed effects on inflammation and on subchondral bone remodeling.
Mechanism language is not outcome language
The distinction matters more than any other point in this article. A review describing what a preparation contains and what it is thought to do biologically is not reporting what it demonstrably does for a patient over years.
Regen.MD holds those two apart deliberately. You can see how that shapes the wider plan in the Regen.MD approach to terrain-first care.
What BMAC is not
It does not regrow or regenerate cartilage
Regen.MD does not claim that BMAC, PRP, Lipogems, or any other orthobiologic regrows or regenerates cartilage. Copy that promises tissue rebuilding goes past what the published evidence supports.
It is not a settled comparison against PRP
The narrative review states that long-term efficacy compared with platelet-rich plasma or autologous conditioned serum has yet to be firmly established. It also notes that variability in preparation methods and in patient selection criteria complicates clinical application, which is one reason results reported at different centers are hard to line up against each other.
It is not a substitute for the rest of the plan
An injection delivers material to one location on one day. Loading, rehabilitation, and the metabolic conditions that either support or obstruct recovery are still doing most of the work, and none of them are replaced by a syringe.
Where BMAC sits for advanced knee osteoarthritis
For adults with knee osteoarthritis, the review reports clinical evidence of short- to mid-term symptomatic relief and functional improvement, and a potential to delay total knee arthroplasty, while stating that findings remain inconsistent.
That is a bridge framing, not a claim of reversal. Advanced knee osteoarthritis is discussed here as a case where an orthobiologic may buy function and time prior to arthroplasty, which is exactly how the underlying evidence is written. The full set of targeted options is on the page for orthobiologic services at Regen.MD.
How the decision is actually made
Entry is a paid, physician-led Clinical Evaluation
Regen.MD does not begin with a procedure. It begins with an evaluation that reviews your history, imaging, and metabolic data before anyone decides whether BMAC is appropriate for you at all.
Candidacy, contraindications, and the specific risks of marrow harvest and injection are determined by a physician who has examined you and read your records. They are not settled from a web page, including this one.
When surgery is the honest answer
Regen.MD does provide surgery when conservative measures have been exhausted. Surgery follows exhausted conservative care rather than opening the conversation, and being told that you have reached that point is a legitimate outcome of an evaluation.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
How the procedure is governed here
Bone marrow aspirate concentrate is a near-universal protocol, and Regen.MD follows the American Society of Interventional Pain Physicians (ASIPP) guidelines for regenerative procedures. Candidacy, technique and aftercare are set in the physician-led evaluation rather than by a standing rule applied to everyone.
Frequently Asked Questions
Does BMAC regrow or regenerate cartilage?
Regen.MD does not claim that BMAC or any other orthobiologic regrows or regenerates cartilage. The narrative review describes proposed biological mechanisms, which is not the same thing as a demonstrated clinical outcome, and it reports that findings across studies remain inconsistent. The conditions evaluated at Regen.MD are approached with that distinction kept in front of the patient.
Is BMAC better than PRP?
That comparison is not settled. The narrative review states directly that long-term efficacy compared with PRP or autologous conditioned serum has yet to be firmly established, so anyone presenting one as clearly superior is going beyond the evidence. Both sit on the page for orthobiologic services at Regen.MD, and which one is discussed depends on the tissue target and your history.
Can BMAC help me delay a knee replacement?
The review reports clinical evidence of short- to mid-term symptomatic relief and functional improvement in adults with knee osteoarthritis, and describes a potential to delay total knee arthroplasty, while noting that findings remain inconsistent. Delay is not avoidance, and no one can promise it for any individual — the Regen.MD patient library covers how that expectation is set before a procedure is scheduled.
Where do peptides fit with BMAC?
They do not overlap. Peptides are discussed at Regen.MD as clinical and educational subjects rather than sold as products, and none of the BMAC evidence cited here speaks to them; see physician-directed peptide therapy for how that subject is handled separately.
Sources
- Park D, Koh HS, Choi YH, Park I. Bone Marrow Aspirate Concentrate (BMAC) for Knee Osteoarthritis: A Narrative Review of Clinical Efficacy and Future Directions. Medicina (Kaunas), 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12113016/ (BMAC enriched with mesenchymal stem cells and bioactive growth factors; proposed effects on inflammation and subchondral bone; short- to mid-term symptomatic relief and functional improvement in adults with knee osteoarthritis; potential to delay total knee arthroplasty; inconsistent findings and variability in preparation and patient selection; long-term efficacy versus PRP or autologous conditioned serum not firmly established).